Meet The Team How-Tos Our Supporters How to Participate in Precision Panc Membership Meeting Minutes Remit of Steering Committee Patient Stories Documents Working with the NHS Patient Public Engagement Meetings Governance News Clinicians Area Clinical Trials What is precision medicine? Information and Support What is Pancreatic Cancer? Current Research Our Researchers Privacy Policy Patients and Carers Contact Us About us Home
Patient 600 recruited Precision-Panc Enters 500th patient to platform Professor Andrew Biankin – it’s about time Pancreatic Cancer is debated in the Scottish Parliament Please watch this very moving video from NIHR West of England Exciting week for the Precision-Panc project Glasgow to host Pancreatic Symposium – Friday 21st May 2021 Survey on the impact of COVID-19 pandemic on pancreatic cancer research Precision-Panc in the Press Precision-Panc / PRIMUS 002 Opens a new site Precision-Panc Re-opens to Recruitment Information on COVID-19 and Pancreatic Cancer from PCUK Precision-Panc and PRIMUS studies suspended to recruitment Precision-Panc Recruits Patient 300 Paul Taylor tells us about his Precision-Panc experience Precision-Panc help raise funds for Pancreatic Cancer Scotland Precision-Panc Recruits Patient 250 Marking World Pancreatic Cancer Day Precision-Panc working with myTomorrows Precision-Panc Roundtable Final Report New Glasgow Cancer Assays by GPOL and Agilent Technologies Precision-Panc opens site 25! Precision-Panc Summer Newsletter Precision-Panc Recruits Patient 200! Precision-Panc Brochure Royal Bournemouth Hospital Opens Finding the right treatment for the patient CRUK animate the Precision-Panc platform CRUK / Precision-Panc Video Professor Biankin receives the Order of Australia in Queen’s Birthday Honours Precision-Panc opens its 20th Site Precision Panc Spring Newsletter Precision-Panc Opens Site 19 Recent Media Pieces Regarding 100 Patient Milestone Site 17 opens for Precision-Panc PRIMUS 002 opens Informing the Future of Genomic Medicine in Scotland Report is Published St James’s University Hospital Opens Precision-Panc Opens its 15th site Glasgow Experts Lead UK Pancreatic Cancer Research 11th site opens to PRECISION-Panc Scotsman Conferences Blogspot November is Pancreatic Cancer Awareness Month First Precision-Panc Trial Opens In Glasgow Cancer Research UK Investment Landscape of pancreatic neuroendocrine cancer Whole Genome Sequencing from EUS biopsies Upcoming Pancreas 2016 Conference Scottish Genome Partnership Announced Identification of four Pancreatic Cancer subtypes offers new treatment insight into the disease First Minister announces £4m ‘Precision Medicine Ecosystem’
Home | News | Precision-Panc working with myTomorrows

Precision-Panc working with myTomorrows

Published: 21st November 2019

World Pancreatic Cancer Day – 21 November 2019

Precision-Panc, University of Glasgow-led pancreatic cancer clinical trials programme, working with myTomorrows to help patients and doctors find personalised treatment options

The University of Glasgow-led and UK-wide Precision-Panc pancreatic cancer clinical trials programme will partner with myTomorrows, a global health technology company, to help patients with pancreatic cancer find new treatments. The announcement comes on World Pancreatic Cancer Day, 21 November, which is dedicated to raising awareness, supporting research and striving for better outcomes to this deadly cancer.

Under the agreement patients who contact Precision-Panc but are unsuitable for any of the currently available trials will be able to use myTomorrows services to seek other trials or Expanded Access Programmes.  If pancreatic patients or their doctors contact myTomorrows they will be informed about other available clinical trials, including Precision-Panc trials or Expanded Access Programmes (EAP).

Expanded Access Programmes, also known as Managed Access Programmes, operate in a medically and legally compliant way to support treatments that are currently not licensed for that indication in a patient’s country of residence. Such treatments can be an option for patients who are in high unmet medical need and have exhausted all registered treatment options and are not eligible to participate in a clinical trial.

Precision-Panc was established in 2017 at the University of Glasgow, with major funding by CRUK,  to bring precision medicine clinical trials to pancreatic cancer patients. Working with the researchers at the CRUK Beatson Institute, CRUK Cambridge Institute, CRUK Manchester Institute, the Institute of Cancer Research, London, the University of Oxford and the NHS, Precision-Panc, has established a network of more than 25 hospitals across the UK that offer these trials.

“In precision medicine, the DNA of each patient’s cancer is analysed with the aim of matching the right treatment to the right patient. Precision medicine aims to enable doctors to better personalise a patient’s treatment, saving time by providing medicines that are more likely to work – and avoiding the toxicity of those that won’t,” explained Professor Andrew Biankin, the Chair and principal investigator of Precision-Panc. 

“At the end of the day, we want our patients to access treatments that are most likely to work for them,” said Professor Biankin. “Our collaboration with myTomorrows will help us reach more pancreatic cancer patients and match them with treatments, either through current clinical trials, or through Expanded Access Programmes.”

myTomorrows is an innovative health technology company that uses artificial intelligence to search for emerging therapies worldwide for cancer, blood disorders and rare diseases.  When a patient or clinician makes contact with myTomorrows, they can speak directly with a patient navigator who is part of myTomorrows’ medical team.  The patient navigator then provides a personalised report listing possible treatment options — through clinical trials or Expanded Access Programmes.  This service is free of charge for patients and their doctors.

“It is a great honour to announce this collaboration on World Pancreatic Cancer Day,” said Steve Glass, COO of myTomorrows. “We look forward to this opportunity to help more pancreatic cancer patients and their families learn about possible treatment options. myTomorrows and Precision-Panc share a commitment to using technology to enable scientific discovery and to help patients access emerging therapies.”

myTomorrows is also working closely with Precision-Panc’s affiliates and patient advocacy organisations to help patients learn about, and access, medicines in development. Precision-Panc affiliates also include the International Cancer Genome Consortium (ICGC), which leads worldwide efforts to map the genomes of both common and rare cancers in order to accelerate the discovery of new treatments.

In addition to 21 November being World Pancreatic Cancer Day, November is also Pancreatic Cancer Awareness Month. Pancreatic cancer is a very complex cancer with few effective treatments.  The five-year survival rate for pancreatic cancer patients is only 9 percent. With 10,000 patients diagnosed annually in the UK (330,000 worldwide) and 9,300 deaths a year, pancreatic cancer is predicted to be the second most lethal cancer after lung cancer by 2025.

This collaboration between myTomorrows and Precision-Panc is currently focused on helping patients in the UK but also aims to expand to other European countries.

For enquiries about myTomorrows or Expanded Access Programmes, please visit www.mytomorrows.com or contact the myTomorrows medical team via medical@mytomorrows.com

For more information please contact Judith Dixon-Hughes 0141 330 2718, Anna Morris 0141 330 7282 or Blanche Hampton 0748 517 3506.

About Precision-Panc For more information about Precision-Panc, visit www.precisionpanc.org

About myTomorrows

myTomorrows operates as a two-sided platform. It serves the interests of both patients and Healthcare Professionals, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialised in Expanded Access Programme regulations and administration and real-world data collection, participating in the evolution of scientific clinical development. myTomorrows has gained experience in running over 25 EAPs over the past 5 years, in more than 40 countries worldwide.

About the International Cancer Genome Consortium’s ARGO (Acceleration Research in Genomic Oncology) (ICGC-ARGO) initiative

ICGC-ARGO is an international network of cancer clinicians, researchers and clinical trials groups working to address the key questions of:

1. How do we use current treatments better?

2. How does a cancer change with time and treatment?

3. How do we practically implement these approaches in healthcare and therapeutic development?

4. How do we advance early detection and ultimately prevent cancer?

© 2024 Precision Panc
Web design by Creatomatic
This site uses cookies.
Read our privacy policy

This site uses cookies for marketing, personalisation, and analysis purposes. You can opt out of this at any time or view our full privacy policy for more information.